Panacea Pharmaceuticals, Inc.

Panacea Pharmaceuticals, Inc.

Panacea Pharmaceuticals, Inc. was founded in 1999 and is based in Gaithersburg, Maryland. Panacea Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic and diagnostic products for cancer and diseases of the central nervous system. It focuses on the development of proteins and biochemical pathways related to cellular regulation and cell cycle abnormalities in oncology, as well as neurodegenerative diseases such as stroke, Alzheimer's disease, and Parkinson's disease. The company’s products include PAN-22, a human anit-HAAH monoclonal antibody for treatment of hepatocellular carcinoma; PAN-622, a Toxin Conjugate to treat carcinoma of the bile duct; and PAN-811 for the treatment of ischemic stroke. In addition, it develops blood, serum, and tissue tests to diagnose and monitor breast, colorectal, lung, and prostate cancers, as well as gene expression test that predicts the response of patients with Chronic Myelogenous Leukemia to imatinib.

Contact Details

Office Address

Panacea Pharmaceuticals, Inc.
209 Perry Parkway, Suite 13
Gaithersburg, MD, USA 20877
Phone: (240) 243-8000
Fax: (240) 465-0450

Executives

Chairman, CEO, and Chief Scientific Officer

Hossein A. Ghanbari

President and COO

Stephen N. Keith

Business Reviews for Panacea Pharmaceuticals, Inc.

Related Companies